| Name | Title | Contact Details |
|---|
IncWorx, Inc. is a Schaumburg, IL-based company in the Software and Internet sector.
Hybrid PayTech World Inc. Develops an Enterprise Ready Mobile Payment Platform for the leading OS's (IOS, Android, BB and Windows 6,7,8). The Corporation's holding, First Equity Strategy LLC, markets itself with the DBA: Hybrid PayTech. International subsidiaries include Hybrid PayTech Asia Inc, Hybrid PayTech Aspac HK Ltd, Vault Acquiring Solutions LLC and Mobi724 Inc. Hybrid PayTech based in Montreal, Canada, is a technology leader in the mobile payment space for EMV (certification level for credit and debit) & MSR (magnetic card reader) credit and debit acceptance. With a global footprint, Hybrid is an enabler of easily-deployable payment systems focusing on authentication, approved security and quick merchant adoption in Fleet, Delivery, Logistics and Retail. The Canadian National Stock Exchange (CNSX) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. This news release does not constitute a solicitation to buy or sell any securities in the United States.
HostBooks is a cloud-based accounting software that enables small businesses and individual taxpayers to manage their finances and take care of their accounting, GST, E way Bill & TDS compliances. Their automated accounting software makes accounting ea...
Itemize end-to-end spend management platform gives you full control and visibility over all your corporate spending from invoices to payments—all in one place.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.